Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Rosmarinic acid methyl ester regulates ovarian cancer cell migration and reverses cisplatin resistance by inhibiting the expression of Forkhead box M1

ABSTRACT: Rosmarinic acid methyl ester regulates ovarian cancer cell migration and reverses cisplatin resistance by inhibiting the expression of Forkhead box M1

PROVIDER: PRJNA665965 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12720225.fastq.gz	Fastqsanger.gz
	SRR12720226.fastq.gz	Fastqsanger.gz
	SRR12720227.fastq.gz	Fastqsanger.gz
	SRR12720228.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Rosmarinic acid methyl ester regulates ovarian cancer cell migration and reverses cisplatin resistance by inhibiting the expression of Forkhead box M1

Project description:Rosmarinic acid methyl ester (RAME), a derivative of rosmarinic acid (RA), has been reported to have several therapeutic effects, including anti-tumor effects, against cervical cancer. However, its anti-tumor effects in ovarian cancer is unclear. In this study, we studied the molecular pathways associated with the anti-tumor effects of RAME in ovarian cancer. To identify the effects of RAME in ovarian cancer, RNA sequencing was performed in RAME-treated ovarian cancer cells; we found that RAME treatment downregulated genes closely involved with the target genes of the transcription factor Forkhead box M1 (FOXM1). It has been reported that FOXM1 is overexpressed in a variety of cancer cells and is associated with cell proliferation and tumorigenesis. Therefore, we hypothesized that FOXM1 is a key target of RAME; this can result in its anti-tumor effects. Treatment of ovarian cancer cells with RAME inhibited cell migration and invasion, as shown by wound healing and transwell migration assays. To examine whether RAME represses the action of FOXM1, we performed quantitative RT-PCR and ChIP-qPCR. Treatment of ovarian cancer cells with RAME decreased the mRNA expression of FOXM1 target genes and the binding of FOXM1 to its target genes. Moreover, FOXM1 expression was increased in cisplatin-resistant ovarian cancer cells, and combination treatment with RAME and cisplatin sensitized the cisplatin-resistant ovarian cancer cells, which was likely due to FOXM1 inhibition. Our research suggests that RAME is a promising option in treating ovarian cancer patients by revealing a novel molecular pathway underlying its anti-tumor effects.

2020-09-28 | GSE158604 | GEO

Rosmarinic Acid Methyl Ester Regulates Ovarian Cancer Cell Migration and Reverses Cisplatin Resistance by Inhibiting the Expression of Forkhead Box M1.

Project description:Rosmarinic acid methyl ester (RAME), a derivative of rosmarinic acid (RA), is reported to have several therapeutic effects, including anti-tumor effects against cervical cancer. However, its anti-tumor effects in ovarian cancer is unclear. In this study, we studied the molecular pathways associated with the anti-tumor effects of RAME in ovarian cancer. To identify the effects of RAME in ovarian cancer, RNA sequencing was performed in RAME-treated ovarian cancer cells; we found that RAME treatment downregulated the genes closely involved with the target genes of the transcription factor Forkhead box M1 (FOXM1). It was reported that FOXM1 is overexpressed in a variety of cancer cells and is associated with cell proliferation and tumorigenesis. Therefore, we hypothesized that FOXM1 is a key target of RAME; this could result in its anti-tumor effects. Treatment of ovarian cancer cells with RAME-inhibited cell migration and invasion, as shown by wound healing and transwell migration assays. To examine whether RAME represses the action of FOXM1, we performed quantitative RT-PCR and ChIP-qPCR. Treatment of ovarian cancer cells with RAME decreased the mRNA expression of FOXM1 target genes and the binding of FOXM1 to its target genes. Moreover, FOXM1 expression was increased in cisplatin-resistant ovarian cancer cells, and combination treatment with RAME and cisplatin sensitized the cisplatin-resistant ovarian cancer cells, which was likely due to FOXM1 inhibition. Our research suggests that RAME is a promising option in treating ovarian cancer patients, as it revealed a novel molecular pathway underlying its anti-tumor effects.

| S-EPMC7601071 | biostudies-literature

Effect of forkhead box M1 in multiple myeloma

Project description:Effect of forkhead box M1 in multiple myeloma

| PRJNA746277 | ENA

Forkhead box E1 (FOXE1) RNAis vs control RNAi in HEKa cells

Project description:Analysis of HEKa cells depleted of Forkhead box E1 (FOXE1). FOXE1 is induced in psoriasis lesions and promotes keratinocytes. Results provide insight into the downstream targets of FOXE1 function in psoriasis.

2021-01-09 | GSE164438 | GEO

Forkhead box F1 overexpression initiates Barrett’s like metaplasia by promoting trans-differentiation and wound repair

Project description:The forkhead box (FOX) family of transcriptional regulators is characterized by a distinct forkhead DNA-binding domain11. FOXF1 gene is highly conserved across species and implicated in embryonic digestive tract morphogenesis. In an in-vitro established model, normal esophageal squamous cells, EPC2, were transfected with FOXF1 to determine pathways regulated by FOXF1 during the squamous to columnar change in cells.

2021-11-12 | GSE122481 | GEO

Biosynthesis of rosmarinic acid in hornworts

Project description:Biosynthesis of rosmarinic acid in hornworts

| PRJEB26010 | ENA

Forkhead box Q1-regulated transcriptome in human breast cancer cells

Project description:Forkhead box Q1-regulated transcriptome in human breast cancer cells

| PRJNA634524 | ENA

Effect of forkhead box M1 in multiple myeloma

Project description:Forkhead Box M1 (FOXM1) is a promising molecular target for high-risk multiple myeloma and relapse and refractory myeloma, but whether FOXM1 is essential in myeloma has not yet been established. To address this knowledge gap, we used Western blotting to measure FOXM1 protein levels in 11 human myeloma cell lines (HMCLs) and then chose the two lines expressing the largest amount of the transcription factor, OPM2 and Delta47, for gene editing using CRISPR-Cas9. In both cases, two independent FOXM1-deficient daughter lines, designated KO-1 and KO-2, were generated. They contained 2 different 10-bp deletions at the target site of their respective guide RNA in case of OPM2 and a 10-bp deletion and 1-bp insertion in case of Delta47. Western analysis confirmed the lack of FOXM1 in all knockout clones. FOXM1-deficient myeloma cells proliferated more slowly than their parental counterparts containing normal levels of FOXM1. Moreover, we added back FOXM1 to FOXM1-KO cells by transfection of a constitutively expressed FOXM1c cDNA gene. The reconstituted OPM2 and Delta47 cells, designated FOXM1 KO-R contained high amounts of FOXM1 protein. Here, we used these cell lines to investigate the role of FOXM1 in regulating the gene expression in multiple myeloma.

2021-07-14 | GSE180018 | GEO

Identification of a forkhead box protein transcriptional network induced in human neutrophils in response to inflammatory stimuli

Project description:We performed the first RNAseq analysis of human primary neutrophils exposed to lipopolysaccharide which revealed a robustly enhanced transcriptional network driven by forkhead box (FOX) transcription factors.

2023-01-02 | GSE221866 | GEO

Effect of Rosmarinic acid in Pseudomonas aeruginosa PAO1 at expression level

Project description:We report a next-generation sequencing of total RNA from Pseudomonas aeruginosa PAO1 grown in presence of rosmarinic acid (RA) 100mM. Data analysis in comparison with cells grown in absence of RA revealed that the plant compound RA induces a broad transcriptional response in this bacterium, quite similar to the quorum sensing response.

2018-07-01 | GSE103620 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data